Tagging and Capturing of Lentiviral Vectors Using Short RNAs

Area of Science:

• Gene Therapy
• Molecular Biology
• Virology

Background:

• Lentiviral (LV) vectors are effective for ex vivo gene delivery but face challenges in vivo, including low efficiency, lack of specificity, and immunogenicity.
• Current engineering strategies for LV vectors include particle modification and protein domain incorporation.
• Synthetic oligonucleotides, like aptamers, offer potential for retargeting and shielding LV vectors from neutralization.

Purpose of the Study:

• To develop strategies for specifically and tightly tethering nucleic acid sequences, such as RNA, to LV vector particles.
• To engineer LV vectors for improved in vivo gene therapy applications.

Main Methods:

• Utilized a bacteriophage lambda N protein-derived RNA binding domain (λN), fused to measles virus hemagglutinin, to bind RNA sequences with a boxB hairpin.
• Employed an RNA aptamer specific to human epidermal growth factor receptor (EGFR) linked to an RNA scaffold containing a boxB motif.
• Bound the aptamer-functionalized scaffold to LV vector particles via the λN protein.

Main Results:

• Confirmed specific binding of the EGFR aptamer to EGFR-expressing cells.
• Demonstrated specific binding of the boxB RNA scaffold to the λN RNA binding domain on the vector.
• Successfully equipped LV vectors with nucleic acid sequences for targeted delivery.

Conclusions:

• LV vectors can be engineered with nucleic acid sequences for enhanced in vivo gene therapy.
• This approach offers a novel strategy to improve LV vector targeting and efficacy.
• The developed method shows promise for overcoming current limitations in LV vector-based gene therapy.